LifeMD (NASDAQ:LFMD) Given New $8.00 Price Target at KeyCorp

LifeMD (NASDAQ:LFMD) had its price target dropped by investment analysts at KeyCorp from $12.00 to $8.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. KeyCorp’s price target indicates a potential upside of 97.29% from the stock’s previous close.

A number of other research analysts have also recently issued reports on the company. Lake Street Capital cut their price objective on LifeMD from $14.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday. Mizuho decreased their price objective on shares of LifeMD from $8.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday. B. Riley reduced their target price on LifeMD from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday. Zacks Research raised LifeMD from a “strong sell” rating to a “hold” rating in a report on Friday, September 5th. Finally, HC Wainwright reduced their price objective on LifeMD from $14.00 to $13.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

LifeMD Stock Performance

LifeMD stock traded down $0.04 on Wednesday, hitting $4.06. The company’s stock had a trading volume of 326,516 shares, compared to its average volume of 1,532,432. The firm has a market cap of $192.28 million, a P/E ratio of -24.09 and a beta of 1.57. The company has a fifty day moving average price of $6.01 and a 200-day moving average price of $8.68. LifeMD has a one year low of $3.43 and a one year high of $15.84. The company has a quick ratio of 0.72, a current ratio of 0.77 and a debt-to-equity ratio of 9.21.

LifeMD (NASDAQ:LFMD) last released its quarterly earnings data on Monday, November 17th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.04). The firm had revenue of $60.17 million during the quarter, compared to the consensus estimate of $62.07 million. During the same quarter in the prior year, the company posted $0.09 EPS. LifeMD has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, equities analysts anticipate that LifeMD will post -0.56 earnings per share for the current year.

Insider Activity

In other news, insider Nicholas P. Alvarez sold 75,000 shares of LifeMD stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $5.92, for a total transaction of $444,000.00. Following the completion of the sale, the insider owned 605,000 shares in the company, valued at $3,581,600. The trade was a 11.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 18.40% of the company’s stock.

Institutional Investors Weigh In On LifeMD

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in LifeMD by 6.7% in the third quarter. Vanguard Group Inc. now owns 2,226,871 shares of the company’s stock valued at $15,120,000 after purchasing an additional 140,749 shares during the last quarter. Royce & Associates LP increased its stake in shares of LifeMD by 3.5% in the 1st quarter. Royce & Associates LP now owns 1,155,231 shares of the company’s stock valued at $6,284,000 after acquiring an additional 39,240 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of LifeMD by 5.4% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 981,894 shares of the company’s stock valued at $5,342,000 after acquiring an additional 50,600 shares during the period. Geode Capital Management LLC boosted its stake in LifeMD by 7.9% during the 2nd quarter. Geode Capital Management LLC now owns 925,173 shares of the company’s stock worth $12,603,000 after acquiring an additional 67,440 shares during the last quarter. Finally, Jump Financial LLC grew its holdings in LifeMD by 205.0% during the second quarter. Jump Financial LLC now owns 515,052 shares of the company’s stock valued at $7,015,000 after purchasing an additional 346,171 shares during the period. 35.52% of the stock is owned by institutional investors and hedge funds.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.